Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 171892, 10 pages
http://dx.doi.org/10.1155/2014/171892
Research Article

Pathway-Driven Discovery of Rare Mutational Impact on Cancer

1Interdisciplinary Program in Bioinformatics, Seoul National University, San 56-1, Shilim-dong, Kwanak-gu, Seoul 151-742, Republic of Korea
2Samsung Genome Institute, Samsung Medical Center, Irwon-ro 81, Seoul 136-710, Republic of Korea
3Department of Statistics, Seoul National University, San 56-1, Shilim-dong, Kwanak-gu, Seoul 151-742, Republic of Korea

Received 31 January 2014; Accepted 14 March 2014; Published 4 May 2014

Academic Editor: FangXiang Wu

Copyright © 2014 TaeJin Ahn and Taesung Park. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Lièvre, J.-B. Bachet, D. le Corre et al., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer,” Cancer Research, vol. 66, no. 8, pp. 3992–3995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. F. Gazdar, “Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors,” Oncogene, vol. 28, supplement 1, pp. S24–S31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. M. Jones, J. Laskin, Y. Y. Li et al., “Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors,” Genome Biology, vol. 11, article R82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. Vaske, S. C. Benz, J. Z. Sanborn et al., “Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM,” Bioinformatics, vol. 26, no. 12, pp. 237–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Drier, M. Sheffer, and E. Domany, “Pathway-based personalized analysis of cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, pp. 6388–6393, 2013. View at Publisher · View at Google Scholar
  6. A. Tae, L. Eunjin, H. Nam, and P. Taesung, “Personalized identification of altered pathways in cancer using accumulated normal tissue data,” Tech. Rep., 2013. View at Google Scholar
  7. P. Khatri, M. Sirota, and A. J. Butte, “Ten years of pathway analysis: current approaches and outstanding challenges,” PLoS Computational Biology, vol. 8, Article ID e1002375, 2012. View at Google Scholar
  8. N. Yu, J. Seo, K. Rho et al., “hiPathDB: a human-integrated pathway database with facile visualization,” Nucleic Acids Research, vol. 40, pp. 797–802, 2011. View at Google Scholar
  9. C. Cheadle, M. P. Vawter, W. J. Freed, and K. G. Becker, “Analysis of microarray data using Z score transformation,” Journal of Molecular Diagnostics, vol. 5, no. 2, pp. 73–81, 2003. View at Google Scholar · View at Scopus
  10. E. Lee, H. Y. Chuang, J. W. Kim, T. Ideker, and D. Lee, “Inferring pathway activity toward precise disease classification,” PLoS Computational Biology, vol. 4, Article ID e1000217, 2008. View at Google Scholar
  11. C. T. Tu and B. S. Chen, “New measurement methods of network robustness and response ability via microarray data’,” PLoS ONE, vol. 8, Article ID e55230, 2013. View at Google Scholar
  12. C. A. Sherman-Baust, K. G. Becker, W. H. Wood III, Y. Zhang, and P. J. Morin, “Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin,” Journal of Ovarian Research, vol. 4, no. 1, article 21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Kalita, B. Tian, B. Gao, S. Choudhary, T. G. Wood, and J. R. Carmical, “Systems approaches to modeling chronic mucosal inflammation,” BioMed Research International, vol. 2013, Article ID 505864, 17 pages, 2013. View at Publisher · View at Google Scholar
  14. The Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, pp. 61–70, 2012. View at Google Scholar
  15. F. R. Mangone, I. G. Bobrovnitchaia, S. Salaorni, E. Manuli, and M. A. Nagai, “PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients,” Clinics, vol. 67, pp. 1285–1290, 2012. View at Google Scholar
  16. B. Singh, P. G. Reddy, A. Goberdhan et al., “p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas,” Genes & Development, vol. 16, no. 8, pp. 984–993, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Astanehe, D. Arenillas, W. W. Wasserman et al., “Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer,” Journal of Cell Science, vol. 121, no. 5, pp. 664–674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Reimand, T. Arak, and J. Vilo, “g:Profiler—a web server for functional interpretation of gene lists (2011 update),” Nucleic Acids Research, vol. 39, no. 2, pp. W307–W315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Reimand, M. Kull, H. Peterson, J. Hansen, and J. Vilo, “g:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments,” Nucleic Acids Research, vol. 35, pp. W193–W200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Warde-Farley, S. L. Donaldson, O. Comes et al., “The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function,” Nucleic Acids Research, vol. 38, no. 2, pp. W214–W220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Wilhelm, C. Carter, M. Lynch et al., “Discovery and development of sorafenib: a multikinase inhibitor for treating cancer,” Nature Reviews Drug Discovery, vol. 5, no. 10, pp. 835–844, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Brose, “Sorafenib benefited patients with RAS, BRAF mutations,” in Proceedings of the European Cancer Congress, Amsterdam, The Netherlands, September-October 2013, abstract no. 3155.
  24. M. J. Ellis and C. M. Perou, “The genomic landscape of breast cancer as a therapeutic roadmap,” Cancer Discovery, vol. 3, pp. 27–34, 2013. View at Google Scholar
  25. S. Banerji, K. Cibulskis, C. Rangel-Escareno et al., “Sequence analysis of mutations and translocations across breast cancer subtypes,” Nature, vol. 486, pp. 405–409, 2012. View at Google Scholar
  26. E. Fox, J. Balko, and C. Arteaga, “Deep kinome sequencing identifies a novel D189Y mutation in the Src family kinase LYN as a possible mediator of antiestrogen resistance in ER+ breast cancer,” Cancer Research, vol. 72, no. 24, 2012. View at Publisher · View at Google Scholar